SERVICE
Drug Screening & Toxicity Study
Drug Screening & Toxicity Study
Biosolvix Technique (High-purity hIPS-CM manufacturing technology)
Cardiac Drug Screening & Toxicity Study
- Exploring Cardiomyocyte-Specific Surface Markers among Various Surface Markers on the Market
- Discovering a novel CD** surface marker that enables over 90% purification of cardiomyocytes
Biosolvix Technique (High-purity hIPS-CM manufacturing technology)
Cardiac Drug Screening & Toxicity Study
- Mature cardiomyocytes occur with an increased surface area.
- Mature cardiomyocytes are the cells Biosolvix intends to use for cardiotoxicity and efficacy assessments.
[Morphology of cardiomyocytes] [Morphology of cardiomyocytes for evaluation of cardiotoxicity and efficacy]
Maturation
Biosolvix Technique (High-purity hIPS-CM manufacturing technology)
Cardiac Drug Screening & Toxicity Study
- Biosolvix's differentiated hIPS-CMs consist of many cells similar to ventricles
- As ventricles are where arrhythmias and coronary artery diseases are found, they are the most suitable cells for efficacy and toxicity testing
Amplitude (mV) | APD 80 (ms) | Vmax (mV/ms) | MDP (mV) | Beat period (ms) | |
Atrial-like hiPSC-CMs | 85.21 ± 7.25 | 131.66 ± 18.41 | 28.95 ± 6.20 | -58.11 ± 3.46 | 234.08 ± 65.82 |
Ventricular like hiPSC-CMs | 109.13 ± 9.43 | 220.43 ± 15.60 | 43.27 ± 9.32 | -69.10 ± 5.61 | 648.97 ± 81.20 |
Our Service
Biosolvix aims to establish animal-free testing services that are most suitable for humans and patients using organoids
Organoid banking
Cancer Organoid
Drug Screening & Toxicity Study
Organ on a chip
Your Full Service Lab for Clinical Trials
Opening hours
Mon
9am - 6pm
Tue
9am - 6pm
Wed
9am - 6pm
Thu
9am - 6pm
Fri
9am - 6pm
Sat - Sun
Closed
WRITE USQuotation Request
© 2023 BioSolvix All rights reserved.